Home › Companies › IONS
Ionis Pharmaceuticals
Market cap $4.49B 166.5M shares (10-Q, Nov 3, 2026) × $26.96 close Nov 17, 2026
Most recent annual filing: 2026-02-26
Q3Q4Q1 ’27Q2Q3Q4Q1 ’28Q2
- Eplontersen ATTR-CM filing2026Eplontersen ATTR-CM filing, 2026, notable
- Pelacarsen filing2026Pelacarsen filing, 2026, notable
- Ionis corporate updateOct–Nov 2026Ionis corporate update, Oct–Nov 2026, material
- Obudanersen Ph3 topline2027Obudanersen Ph3 topline, 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a
six-month window. Deeper blue means more of the thesis rides on the event; it is not a
view on the stock.
Pipeline (29 active programs)
TRYNGOLZA
olezarsen
DAWNZERA
donidalorsen
WAINUA
eplontersen
SPINRAZA
nusinersen
QALSODY
tofersen
TEGSEDI
inotersen
WAYLIVRA
volanesorsen
ZANVASTRO
zilganersen · ION373
obudanersen
ION582
Hibsago
bepirovirsen · GSK3228836
pelacarsen
TQJ230
sefaxersen
IONIS-FB-LRx · RO7434656
ulefnersen
sapablursen
salanersen
ION306
ION826
AZD4063 - Undisclosed indication Phase 1 AstraZeneca
opemalirsen
tominersen
TEGSEDI
Technology platforms
Discontinued (1)
- sefaxersen — Geographic Atrophy · insufficient efficacy to advance into Phase 3 development
Capital (as filed)
- Cash
- $296M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $1.59B Sep 30, 2026
- Long-term investments
- $561M Sep 30, 2026
- Operating cash flow
- −$179M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $1.88B cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (7)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (7 calls)
Every verdict Biotech Distilled has published on Ionis Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-09-10 Watch Ionis Pharmaceuticals (IONS) — Scientific Deep Dive for Olezarsen, Zilganersen and the RNA-Targeted Pipeline Science is proven and balance sheet is funded, but the flagship TRYNGOLZA booked only $4.6M in Q2 against a >$3B peak-sales claim, making it prudent to wait for one clean print at the new price before committing.
- 2026-09-23 Watch UPDATE: Ionis Pharmaceuticals (IONS) - The Streak Breaks FUSION's Phase 3 win repairs scientific credibility but does not answer the commercial question; TRYNGOLZA's Q3 print remains the gating event.
- 2026-09-24 Watch UPDATE: Ionis Pharmaceuticals (IONS) - Two for Two, Minus the Number Sefaxersen's Phase 3 proteinuria win is a second positive readout in 48 hours but provides no number and does not address the TRYNGOLZA commercial question.
- 2026-10-22 Watch UPDATE: Ionis Pharmaceuticals (IONS) - Approved, With a Box on It Bepirovirsen approval retires regulatory risk on the best partnered asset but the boxed label, China carve-out, and capped royalty leave the TRYNGOLZA commercial question as the sole gating event.
- 2026-10-24 Watch UPDATE: Ionis Pharmaceuticals (IONS) - Here's the Number Sefaxersen's 43.1% proteinuria reduction is real and regulator-relevant but does not clearly beat iptacopan and does nothing for the TRYNGOLZA commercial question.
- 2026-11-10 Avoid UPDATE: Ionis Pharmaceuticals (IONS) - The $9 Million Answer TRYNGOLZA's $9.3M Q3 print decisively failed the pre-committed <$20M Pass trigger, with guidance cut in half and no sequential growth projected for Q4, making the >$3B peak-sales claim dependent on an untested 2027 payer cycle.
- 2026-11-18 Avoid UPDATE: Ionis Pharmaceuticals (IONS) - The Tau Gap Closes, Partly Diranersen's Week 96 functional signal and EU TRYNGOLZA approval are positive for the science but neither addresses the U.S. demand failure that triggered the downgrade.
- Avoid call · opened Nov 10, 2026 at $28.19 · -4.4% vs XBI -6.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The FDA has granted Priority Review of bepirovirsen, with a PDUFA action date of October 26, 2026.”
matched to Bepirovirsen · regulatory decision / matched to Obudanersen · topline data -
“The FDA has granted Priority Review of zilganersen, with a Prescription Drug User Fee Act, or PDUFA, action date of September 22, 2026.”
matched to Ionis (corporate) · other
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (33)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first.
Releases captured from Sep 22, 2026;
filings from March 2026.
Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseTRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)→ BD updateSummary on the release
- Nov 17, 2026ReleaseDiranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease→ BD updateThe EU just approved TRYNGOLZA for sHTG — but only for TG ≥880 mg/dL, the narrower label I flagged in November 9's update. Meanwhile, diranersen's two-year CTAD data show a 38% CDR-SB slowing and, critically, a 30% functional endpoint effect that was zero at 18 months — the exact signal that had been missing from every prior tau program.
- Nov 12, 2026ReleaseIonis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
- Nov 10, 2026ReleaseIonis to present at upcoming investor conferences
- Nov 9, 2026ReleaseIonis reports third quarter 2026 financial results and highlights progress on key programs→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99 EXHIBIT 99.1→ BD updateTRYNGOLZA's Q3 print landed at $9.3 million — well below the $20 million floor I said would convert this thesis to a Pass — and Ionis simultaneously cut full-year guidance from $100–110M to ~$50M. The stock dropped 21% on the day, and Roche quietly terminated two additional collaborations.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseIonis to hold third quarter 2026 financial results webcast
- Oct 23, 2026ReleaseIonis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)→ BD updateSummary on the 8-K
- Oct 23, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateSefaxersen's IMAgINATION data finally has a number attached — 43.1% proteinuria reduction vs. placebo (p<0.0001) — and it beats the iptacopan benchmark I said to watch for. The stock shrugged anyway, because the question gating this thesis still isn't sefaxersen's.BD extracted 1 program update from this document → IONS pipeline
- Oct 22, 2026ReleaseIonis ranked #1 on Science’s Top Employers list
- Oct 21, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateHIBSAGO (bepirovirsen) won FDA approval after the close on October 20 — six days ahead of the PDUFA — with a 19% functional cure rate against less than 1% on standard of care, but a Boxed Warning and a tighter-than-expected label narrow the addressable pool and cap Ionis's royalty upside in ways the headline doesn't show.BD extracted 1 program update from this document → IONS pipeline
- Oct 20, 2026ReleaseIonis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)BD extracted 1 program update from this document → IONS pipeline
- Oct 16, 2026ReleaseTRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)BD extracted 1 program update from this document → IONS pipeline
- Sep 23, 2026ReleaseIonis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)→ BD updateSummary on the 8-K
- Sep 23, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateSefaxersen's Phase 3 IMAgINATION study hit its primary endpoint — statistically significant UPCR reduction vs. placebo at 37 weeks in 459 IgAN patients — answering the thesis question I posed in the deep dive: was 2026 bad luck or a pattern? Two consecutive Phase 3 wins in one week say it's looking more like bad luck.BD extracted 1 program update from this document → IONS pipeline
- Sep 22, 2026ReleaseIonis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS→ BD updateAfter three straight Phase 3 failures, ulefnersen just hit its primary endpoint in FUS-ALS — a small trial but a real signal that Ionis's platform can still translate target knockdown into patient benefit. Here's what it means for the thesis.BD extracted 1 program update from this document → IONS pipeline
- Sep 4, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Sep 4, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Jul 29, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Jul 29, 202610-QQuarterly report
- Jul 10, 20268-KCurrent report: Reg FD disclosure
- Jul 9, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Jun 24, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Jun 12, 20268-KCurrent report: other events
- Jun 8, 20268-KCurrent report: officer / director change, shareholder vote, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- May 28, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Apr 29, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Apr 29, 202610-QQuarterly report
- Apr 23, 2026DEFA14AProxy soliciting material
- Apr 23, 2026DEF 14AProxy statement
- Apr 21, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Mar 9, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)